NYSE · Healthcare · Drug Manufacturers - General · USA
Abbvie Inc is a mega cap company (market value over $200 billion) in the Drug Manufacturers - General industry.
AbbVie is a global biopharmaceutical company that researches, develops, manufactures and sells innovative medicines and therapies. Its portfolio spans immunology, neuroscience, oncology, aesthetics and eye care, with products addressing autoimmune diseases, neurologic conditions, cancers and cosmetic applications. The company operates as a single global business segment serving patients across North America, Europe, Japan and other markets worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Abbvie Inc stock.
Overvalued: intrinsic value $107.26 per share, market price $282.68, margin of safety -163.5% (as of 2026-10-19).
Discounting its cash flows at 7.0% (average of 3 methods) values the shares at $107.26; the price of $282.68 is 164% above that value, and 83% of that value comes from beyond year five.
Leak Score: 50/100 on 10 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
7 more in this industry show a wider margin of safety.
ABBV is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.0% (average of 3 methods) values the shares at $107.26; the price of $282.68 is 164% above that value, and 83% of that value comes from beyond year five.
$107.26 per share (as of the 2026-10-19 close), against a market price of $282.68. That is a margin of safety of -163.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price needs faster growth than we project for any company. It is betting on an exception. Yearly sales growth the price needs: 42.3%. Yearly sales growth it has sustained: 3.7%.
50 out of 100, which we rate "Weak Signal", on 10 of 12 value investing signals.